

Oligometastatic prostate cancer: molecular imaging and clinical management implications in the era of precision oncology

Hossein Jadvar, MD, PhD

Division of Nuclear Medicine
Department of Radiology
University of Southern California
Los Angeles, CA, USA

Keywords: oligometastatic, prostate, cancer, imaging, management

Number of Words (including references): 1749

Acknowledgment: Supported by the National Institutes of Health grant numbers R21-EB017568 and P30-CA014089.

Address for correspondence:

Hossein Jadvar, MD, PhD
Division of Nuclear Medicine
Department of Radiology
University of Southern California
2250 Alcazar Street, CSC 102
Los Angeles, CA 90033
Tel: 323-442-1107
Fax: 323-442-3253
Email: jadvar@med.usc.edu

Immediate Open Access: Creative Commons Attribution 4.0 International License (CC BY) allows users to share and adapt with attribution, excluding materials credited to previous publications.

License: <https://creativecommons.org/licenses/by/4.0/>

Details: <http://jnm.snmjournals.org/site/misc/permission.xhtml>.

The underlying biology of prostate cancer is complex that evolves from initial tumorigenesis to metastatic potentiation and castrate resistance. Metastases source directly from the primary tumor site but also can occur from an established metastatic site to another new metastatic site or even to the surgical bed leading to local recurrence (1, 2). This cross-metastatic site seeding is often associated with heterogeneous tumor clones with varying degrees of aggressiveness and resistance to therapy. The spatiotemporal clonal diversity of metastases suggest that not all metastases are created clinically equal and that targeted treatment of some key metastases, if clearly identifiable, can potentially improve systemic control of cancer and overall outcome, even in the setting of occult micrometastases.

Hellman and Weichselbaum proposed existence of a clinical state that they termed as oligometastatic disease as an intermediate step in cancer progression from a localized confined process to a disseminated state (spectrum theory of cancer)(3, 4). The oligometastatic state is associated with a limited number of detectable metastases (variably defined as 1 to 3, 4, or 5 sites) with distinct presumably less aggressive biology (immature metastatic competence) in comparison to widespread polymetastatic disease (5, 6). The postulate here is that oligometastatic lesions are early along their evolutionary line of metastatic potentiation. The management implication then follows that in some patients with oligometastases, cure may still be possible with definitive metastasis-directed therapies (MDTs) and minimal systemic toxic effects (7-14). Also the oligometastatic colony is removed or

destroyed before it can evolve into more aggressive phenotype with untoward consequences locally and potential for facilitating tumor seeding of other sites.

Diagnosis of oligometastatic disease relies fundamentally on performance of diagnostic imaging tools, which are advancing rapidly (15-18). The advent of more sensitive imaging technologies and availability of safe and effective localized non- or minimally-invasive treatment options (e.g. stereotactic body radiation therapy-SBRT, local ablation or surgical techniques) in the era of precision and personalized cancer care have lead to increasing incidence and clinical interest in oligometastatic disease. Although the case for treating patients with limited metastatic disease is not a recent phenomenon, but as Reyes et al point out, the beneficial evidence for treatment of oligometastases in a number of cancers (breast, lung, colorectal, kidney, melanoma, sarcoma) is overall weak (4).

Few studies have focused on treatment and clinical outcomes of oligometastatic prostate cancer. Azzam et al employed SBRT to treat up to 4 metastases in patients with recurrent prostate cancer after prior definitive treatment (19). Median survival was significantly longer in patients with treated oligometastatic disease than those with treated polymetastatic disease (>3 years vs. 11 months, $p=0.02$). More recently, Ost and colleagues reported on the results of a prospective, randomized, multicenter phase II trial comparing surveillance to MDT for oligometastatic prostate cancer recurrence (STOMP trial, NCT01558427)(20). Sixty-two asymptomatic non-castrate men with prior definitive treatment for

primary prostate cancer who presented with biochemical recurrence with three or fewer extracranial metastases on choline PET were randomized (balanced on the basis of PSA doubling time and nodal versus non-nodal metastases) to either surveillance or MDT (surgery or SBRT) of oligometastases. The primary end point was androgen-deprivation therapy (ADT)-free survival with a median follow-up time of 3 years. The ADT-free survival was significantly longer with MDT than with surveillance alone (21 months vs. 12 months, HR 0.55, log-rank $p=0.08$, per-protocol analysis). Interestingly, 35% of patients undergoing surveillance experienced relatively short duration spontaneous PSA declines without any therapy while 30% of patients treated with MDT progressed to polymetastatic disease within the first year. A similar phase II trial (ORIOLE) is also underway that randomizes men with non-castrate oligometastatic prostate cancer (identified on the PSMA ligand imaging with ^{18}F -DCFPyl PET/CT) to either surveillance or selective ablative radiotherapy (SABR) of metastatic lesions with the primary clinical endpoint of progression at 6 month from randomization (NCT02680587)(21). Safety, efficacy and effects of SABR-directed therapy of oligometastases on circulating tumor cells, circulating tumor DNA, and immunologic response will also be measured. Nevertheless, it still remains to determine whether the strategy of MDT-directed therapy of oligometastases (with or without additional systemic therapy to combat invisible micrometastases) lead to improved disease-specific or overall survival (22).

In view of above remarks, several issues still need to be settled before the concept of oligometastases can take potential hold in the routine clinical management of

patients with prostate cancer. A biological anchor is needed to decipher whether oligometastatic lesions are indeed different from polymetastatic lesions and how “oligo” lesions evolve to “poly” lesions (23). Some work has shown that oligometastases have different microRNA expression profile than polymetastases (5). Additional studies that fully characterize the differential genotype and phenotype will not only advance our basic understanding of cancer evolution but also can be helpful in identifying those patients who most likely would benefit from MDT-directed therapy of oligometastases. This will elucidate if we should “catch them all or not” as Murphy et al elaborated (24). It can also provide opportunities for development of sophisticated interventions that may retain the biological behavior of these few metastases as indolent, decreasing the risk for metastasis-to-metastasis seeding. There is need for a standardized definition of oligometastases preferably based on some biologic markers that can be tailored to a defined molecular imaging technique rather than the current situation in which detection and localization of oligometastatic lesions are primarily dependent on the type and sensitivity of the diagnostic imaging that is employed. Additionally there is lack of uniformity in describing the oligometastatic condition as it is now used in various clinical scenarios with likely different underlying biology (25). These include synchronous oligometastases (with untreated primary cancer), metachronous disease (after definitive therapy of primary cancer), and induced oligometastases (when widespread disease is eradicated by systemic therapy but few drug shielded or resistant lesions remain).

In conclusion, while the concept of oligometastasis is interesting but there is still more basic research that needs to be done to establish it firmly as a distinct biological entity along the natural history of prostate cancer. The current unsystematic approach in detection and management of oligometastatic prostate cancer will need to be standardized so that future clinical trials can be designed appropriately and more importantly compared properly. These critical prerequisites will elucidate whether detection and management of oligometastases should be incorporated into the routine clinical management of patients with prostate cancer.

References

1. Gundem G, Loo PV, Kremeyer B, et al. The evolutionary history of lethal metastatic prostate cancer. *Nature* 2015; 520:353-357.
2. Hong MKH, Macintyre G, Wedge DC, et al. Tracking the origins and drivers of subclonal metastatic expansion in prostate cancer. *Nat Commun* 2015; 6:6605.
3. Hellman S, Wichselbaum RR. Oligometastases. *J Clin Oncol* 1995; 13:8-10.
4. Reyes DK, Pienta KJ. The biology and treatment of oligometastatic cancer. *Oncotarget* 2015; 6:8491-8524.
5. Lussier YA, Xing HR, Salama JK, et al. MicroRNA expression characterizes oligometastasis(es). *PLoS One* 2011; 6:e28650.
6. Stevens DJ, Sooriakumaran P. Oligometastatic prostate cancer. *Curr Treat Options Oncol* 2016; 17:62.
7. Muldermans JL, Romak LB, Kwon ED, et al. Stereotactic body radiation therapy for oligometastatic prostate cancer. *Int J Radiat Oncol Biol Phys* 2016; 95:696-702.
8. Viela RA, Navarro NF, Faria ET, et al. Use of stereotactic body radiation therapy for oligometastatic recurrent prostate cancer: a systematic review. *J Med Imaging Radiat Oncol* 2018. [Epub ahead of print]
9. Morgans AK, Hussain M. Risk stratification in oligometastatic prostate cancer: where are we and what do we need? *Curr Opin Urol* 2017; 27:547-552.
10. Singh D, Yi WS, Brasacchio RA, et al. Is there subset of patients with prostate cancer who develop oligometastases? *Int J Radiat Oncol* 2004; 58:3-10.
11. Clement JM, Sweeney CJ. Evolving treatment of oligometastatic hormone-sensitive prostate cancer. *J Oncol Pract* 2017; 13:9-18.
12. De Bruycker A, Lambert B, Claeys T, et al. Prevalence and prognosis of low-volume, oligorecurrent, hormone-sensitive prostate cancer amenable to lesion ablative therapy. *BJU Int* 2017. [Epub ahead of print]
13. Bernard B, Gershman B, Karnes RJ, et al. Approach to oligometastatic prostate cancer. *Am Soc Clin Oncol Educ Book* 2016; 35:119-129.
14. Martinez-Fernandez MI, Perez Gracia JL, Gil-Bazo I, et al. Stereotactic body radiation therapy (SBRT) delays the emergence of castration resistance in patients with oligometastatic prostate cancer. *Clin Transl Oncol* 2016; 18:743-747.
15. deSouza NM, Liu Y, Chiti A, et al. Strategies and technical challenges for imaging oligometastatic disease: recommendations from the European Organization for Research and Treatment of Cancer imaging group. *Eur J Cancer* 2018; 91:153-163.
16. Joice GA, Rowe SP, Pienta KJ, et al. Oligometastatic prostate cancer: shaping the definition with molecular imaging and an improved understanding of tumor biology. *Curr Opin Urol* 2017; 27:533-541.
17. Guler OC, Engels B, Onal C, et al. The feasibility of prostate-specific membrane antigen positron emission tomography (PSMA PET/CT)-guided radiotherapy in oligometastatic prostate cancer patients. *Clin Transl Oncol* 2018; 20:484-490.
18. Larbi A, Dallaudiere B, Pasoglou V, et al. Whole body MRI (WB-MRI) assessment of metastatic spread in prostate cancer: therapeutic perspectives on targeted management of oligometastatic disease. *Prostate* 2016; 76:1024-1033.
19. Azzam G, Lanciano R, Arrigo S, et al. SBRT: an opportunity to improve quality of life for oligometastatic prostate cancer. *Front Oncol* 2015; 5:101.

20. Ost P, Reynders D, Decaestecker K, et al. Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial. *J Clin Oncol* 2018; 36:446-454.
21. Radwan N, Phillips R, Ross A, et al. A phase II randomized trial of Observation versus stereotactic ablative Radiation for Oligometastatic prostate CanEr (ORIOLE). *BMC Cancer* 2017; 17:453.
22. Dorff TB, Sweeney CJ. Chemotherapy for oligometastatic prostate cancer. *Curr Opin Urol* 2017; 27:553-558.
23. Sonpavde G. The biology of prostate cancer metastases: does oligo differ from polymetastatic? *Curr Opin Urol* 2017; 27:542-546.
24. Murphy DG, Sweeney CJ, Tombal B. “Gotta catch ‘em all”, or do we? Pokemet approach to metastatic prostate cancer. *Eur Urol* 2017; 72:1-3.
25. Tosoian JJ, Gorin MA, Ross AE, et al. Oligometastatic prostate cancer: definitions, clinical outcomes and treatment considerations. *Nat Rev Urol* 2017; 14:15-25.



The Journal of
NUCLEAR MEDICINE

Oligometastatic prostate cancer: molecular imaging and clinical management implications in the era of precision oncology

Hossein Jadvar

J Nucl Med.

Published online: July 20, 2018.

Doi: 10.2967/jnumed.118.213470

This article and updated information are available at:

<http://jnm.snmjournals.org/content/early/2018/07/19/jnumed.118.213470.citation>

Information about reproducing figures, tables, or other portions of this article can be found online at:

<http://jnm.snmjournals.org/site/misc/permission.xhtml>

Information about subscriptions to JNM can be found at:

<http://jnm.snmjournals.org/site/subscriptions/online.xhtml>

JNM ahead of print articles have been peer reviewed and accepted for publication in *JNM*. They have not been copyedited, nor have they appeared in a print or online issue of the journal. Once the accepted manuscripts appear in the *JNM* ahead of print area, they will be prepared for print and online publication, which includes copyediting, typesetting, proofreading, and author review. This process may lead to differences between the accepted version of the manuscript and the final, published version.

The Journal of Nuclear Medicine is published monthly.
SNMMI | Society of Nuclear Medicine and Molecular Imaging
1850 Samuel Morse Drive, Reston, VA 20190.
(Print ISSN: 0161-5505, Online ISSN: 2159-662X)

© Copyright 2018 SNMMI; all rights reserved.

The logo for the Society of Nuclear Medicine and Molecular Imaging (SNMMI) consists of the letters 'S', 'N', 'M', and 'I' arranged in a 2x2 grid. Each letter is white and set within a red square. To the right of this grid, the full name of the society is written in a stacked, sans-serif font: 'SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING'.

SOCIETY OF
NUCLEAR MEDICINE
AND MOLECULAR IMAGING